Our DARPin Therapeutics

A new generation of multi-functional protein medicines

LifeSpring Biotech is helping lead the way in the development of DARPin therapeutics—a powerful new class of engineered protein drugs inspired by naturally occurring binding proteins. These customizable molecules are designed to address challenges that traditional protein-based therapies often cannot overcome.

DARPin medicines have already shown strong clinical promise across multiple therapeutic areas, with several programs progressing all the way to the registrational stage. Their stability, precision, and modular architecture make them uniquely suited for complex disease targets.

Building on years of innovation and clinical leadership in the DARPin field, we are expanding the possibilities of this platform for patients. Our pipeline now includes Radio-DARPin therapies, which combine targeted binding with therapeutic radioisotopes, as well as next-generation immune cell engagers, including our adaptable Switch-DARPin technologies.

Together, these advancements represent a new era of protein therapeutics—one with the potential to deliver more selective, potent, and safer treatments for some of the world’s most challenging diseases.

Manufacturing DARPins: Built for Speed, Efficiency, and Scaledelivery

DARPin molecules are small, highly stable proteins that do not require complex post-translational modification. Because of this, they can be produced rapidly and at scale through streamlined bacterial fermentation. This process enables the manufacturing of clinical-grade batches in as little as seven to ten days, significantly accelerating development timelines compared with traditional biologics.

Partner With Us

Our scaffolds override subcellular trafficking patterns for a target and improve ADC delivery to the lysosome. Reach out to learn more.